Navigation Links
PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a
Date:4/2/2011

Berlin, Germany, 02 April 2011: Highly exciting new data presented today at the International Liver CongressTM found Pegylated Interferon-lambda (PegIFN-lambda) shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha (PegIFN-alpha-2a), the current standard of care in chronic HCV.1

The study results are so important because they show PegIFN-lambda could provide relief for the 20% of HCV patients who have to undergo dose reduction, or cease treatment, on PegIFN-alpha-2a a part of the current HCV standard of care.2

The trial shows that PegIFN-lambda provides higher rapid virological response (RVR) and complete early virological response (cEVR) than PegIFN-alpha-2a, even in patients with an unfavourable IL28B genotype which predisposes patients to be resistant to treatment.

Both RVR and cEVR are important markers of a drug's ability to combat HCV infection: RVR is measured as undetectable HCV RNA at week 4 of therapy, maintained up to end of treatment; cEVR is detectable HCV RNA at week 4, but undetectable at week 12, maintained up to end of treatment.

Results at week 12 of the trial show that those HCV genotype 1 and 4 patients given 180g of PegIFN-lambda achieved RVR 14.7% of the time and cEVR 55.9% of time, compared to 5.8% RVR and 37.9% cEVR in patients given the same dose of PegIFN-alpha-2a.

The study also found PegIFN-lambda was associated with fewer hematologic (blood cell) toxicities, flu-like symptoms, musculoskeletal symptoms, dose reductions and premature discontinuations than the same dose of PegIFN-alpha-2a. However, in the higher dose groups elevations of ALT and bilirubin were observed which may represent drug related toxicity.

Professor Heiner Wedemeyer, EASL's Secretary General, commented: "These are clearly very early results but the combination of better virological response and fewer side effects makes these very exciting findings. The percentage of current HCV patients that have to cease treatment, or have their dose lowered, due to the side effects associated with PegIFN-alpha-2a is high. We look forward to seeing the sustained virological responses, which will inform us whether PegIFN-lambda could be used as a replacement for PegIFN-lambda in the future."

In the ongoing randomized phase-IIB trial, 526 treatment-nave HCV patients received ribavirin with weekly subcutaneous PegIFN-alpha-2a a 180g dose or PegIFN-lambda either a 120, 180 or 240g doses.

In HCV genotype 2 and 3 patients, 180g of PegIFN-lambda led to 75.9% RVR and 96.6% cEVR, compared to 31% RVR and 86.2% cEVR for the same dose of PegIFNα-2a. PegIFN-lambda exerts its antiviral effects through a different receptor to PegIFN-alpha-2a.1


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. First blinded study of venous insufficiency prevalence in MS shows promising results
2. People with anxiety disorder less able to regulate response to negative emotions, study shows
3. Poll Shows Eroding Support for Health Reform
4. Protecting patients: Study shows that Johns Hopkins flu vaccination rates twice national average
5. Compound shows promise against intractable heart failure
6. Drama or reality TV: Do medical shows depict proper first aid for seizures?
7. TV Shows Often Botch Proper Seizure Responses
8. UQ research shows canecutters disease on the rise among travelers
9. Brain Scan Shows What Beauty is Worth
10. Untreated poor vision in elderly linked to dementia, University of Michigan study shows
11. New research shows emotional impact of low sexual desire and associated distress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Story Highlights: ... the health care industry is causing providers to review ... Deloitte offers a suite of solutions for health care ... cost optimization: labor resource analysis, revenue cycle optimization and ... outcomes and better economics ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
Breaking Medicine Technology: